Indivi

The AI engine Fit Assessment

Beta

Indivi effectively utilizes remote monitoring technologies to identify and validate digital biomarkers, advancing clinical trials in neuroscience.

Blurb

Indivi develops functional biomarkers that measure key disability concepts of importance for drug development trials in neuroscience

HQ Location

Basel (Switzerland)

Founded

2012

Employees

51 - 200

Total funding raised

$23.00M

Funding Status

Venture - Series Unknown, $18.80M, November 12, 2025
Subspaces
  • Digital Biomarkers Development

Indivi is a TechBio company developing multi-modal deep phenotyping technologies and derived decision-making biomarkers as drug development tools for neurological diseases for instance in the form of sensor-derived measurements generated from smartphone-based assessments of cognition and motion.



Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotyping instruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias.



Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in clinical development, data science, signal processing engineering, and advanced analytics including computational intelligence.



Through end-to-end collaborative endeavours with biopharmaceutical companies, Indivi is poised to continue its growth to improve the probability of technical and regulatory success in neuroscience drug development.